公开(公告)号：US20170002425A1

公开(公告)日：2017-01-05

申请号：US15153240

申请日：2016-05-12

Applicant: TOPPAN PRINTING CO., LTD.

Inventor： Shiro KITANO ,  Takeshi YAMADA

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/57419 ,  G01N2333/475 ,  G01N2333/515 ,  G01N2800/52 ,  G01N2800/7014

Abstract: A method for predicting long-term efficacy of a VEGF inhibitor of the present invention includes determining whether or not an RAS gene-derived nucleic acid or an RAS protein is present in a blood sample collected from a subject, determines whether the RAS gene-derived nucleic acid in the blood sample is a wild type or a mutant or whether the RAS protein in the blood sample is a wild type or a mutant, determining that an antitumor effect resulting from the VEGF inhibitor is highly likely to last for a long period of time in the subject in a case where a wild-type RAS gene-derived nucleic acid or a wild-type RAS protein is detected in the blood sample and a mutant RAS gene-derived nucleic acid or a mutant RAS protein is not detected in the blood sample.

Abstract translation: 用于预测本发明的VEGF抑制剂的长期功效的方法包括确定RAS基因衍生的核酸或RAS蛋白是否存在于从受试者收集的血液样品中，确定RAS基因衍生的 血液样品中的核酸是野生型或突变体，或血液样品中的RAS蛋白是野生型还是突变体，确定由VEGF抑制剂产生的抗肿瘤作用很可能长时间持续 在血液样本中检测到野生型RAS基因衍生的核酸或野生型RAS蛋白质的情况下，在未检测到突变体RAS基因的核酸或突变型RAS蛋白质的情况下， 血液样本。